Spruce is developing novel therapies for rare endocrine diseases. The company’s lead product candidate for the treatment of congenital adrenal hyperplasia (CAH) is intended to correct hormone imbalances, giving patients a therapeutic option that treats their underlying disease while reducing their steroid burden.